Current Neuro-Oncology
Volume
25 Number 7
15 April 2023
Home > Publications > Current Neuro-Oncology > Volume 25, Year 2023 > Number 7, 15 April
Haider AS, Ene CI, Palmisciano P,
Haider M, Rao G, Ballester LY, Fuller GN.
Concurrent
IDH1 and IDH2 mutations in glioblastoma: A case report.
Front
Oncol. 2023 Apr 3;13:1071792∟.
doi: 10.3389/fonc.2023.1071792∟.
PMID: 37077830∟.
Case report. ˍ
Goddard J, Castle J, Southworth E,
Fletcher A, Crosier S, Martin-Guerrero I, García-Ariza M,
Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O,
Goschzik T, Pietsch T, Sill M, Pfister SM, Rutkowski S, Richardson
S, Hill RM, Williamson D, Bailey S, Schwalbe EC, Clifford SC,
Hicks D.
Molecular
characterisation defines clinically-actionable heterogeneity
within Group 4 medulloblastoma and improves disease
risk-stratification.
Acta
Neuropathol. 2023 Apr 4∟.
doi: 10.1007/s00401-023-02566-0∟.
PMID: 37014508∟.
Laboratory investigation, Observational
study. ˍ
Kim MJ, Park JS, Jeun SS, Ahn S.
A
clinical evaluation of cystic features in patients with newly
diagnosed glioblastoma with IDH-wildtype.
Clin
Neurol Neurosurg. 2023 Apr 4;228:107708∟.
doi: 10.1016/j.clineuro.2023.107708∟.
PMID: 37043844∟.
Observational
study. ˍ
Moraes FY, Gouveia AG, Marta GN, Viani GA.
Radiotherapy
combined or not with chemotherapy in adult or pediatric patients
with brainstem glioma: a population-based study.
Rep
Pract Oncol Radiother. 2023 April 4;28(2):181-188∟.
doi: 10.5603/RPOR.a2023.0016∟.
PMID: 37456697∟.
Observational study. ˍ
Allwohn L, Wolfgang J, Onken J,
Wasilewski D, Roohani S, Zips D, Ehret F, Kaul D.
Treating
oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted
and isocitrate dehydrogenase-mutant patient cohort.
Clin
Transl Radiat Oncol. 2023 Apr 5;41:100626∟.
doi: 10.1016/j.ctro.2023.100626∟.
PMID: 37216045∟.
Observational study. ˍ
Kim EY, Vavere AL, Snyder SE, Chiang J, Li Y, Patni T, Qaddoumi I,
Merchant TE, Robinson GW, Holtrop JL, Shulkin BL, Bag
AK.
[11C]-methionine positron emission
tomography in the evaluation of pediatric low-grade
gliomas.
Neurooncol
Adv. 2024 Apr 5;6(1):vdae056. doi:
10.1093/noajnl/vdae056. PMID:
38680989. Observational study. ˍ
Jones C, Straathof K, Fouladi M,
Hargrave D, Prados M, Resnick A, Doz F, Jones DTW, Mueller
S.
Evaluating
preclinical evidence for clinical translation in childhood brain
tumours: Guidelines from the CONNECT, PNOC, and ITCC brain
networks.
Front
Oncol. 2023 Apr 5;13:1167082∟.
doi: 10.3389/fonc.2023.1167082∟.
PMID: 37091147∟.
Perspective. ˍ
Lee PY, Wei YT, Chao KC, Chu CN, Chung WH, Wang TH.
Anti-epileptic
drug use during adjuvant chemo-radiotherapy is associated with
poorer survival in patients with glioblastoma: A nationwide
population-based cohort study.
J
Cancer Res Ther. 2023 Apr 5;20(2):555-562. doi:
10.4103/jcrt.jcrt_750_22. PMID:
38687925. Observational study. ˍ
Ma X, Liu J.
Predictive
value of MRI features on glioblastoma.
Eur
Radiol. 2023 Apr 5∟.
doi: 10.1007/s00330-023-09535-x∟.
PMID: 37020071∟.
Editorial. ˍ
Refers
to:
Kim
M, et al. Vessel size and perfusion-derived vascular habitat
refines prediction of treatment failure to bevacizumab in
recurrent glioblastomas: validation in a prospective cohort. Eur
Radiol. 2022 Oct 15∟.
doi: 10.1007/s00330-022-09164-w∟.
PMID: 36242633∟.
Interventional study˰ ˍ
S Rai HI, Agrawal D, Singh M, Kale
SS.
Early
Gamma Knife Therapy (Without EBRT) in Operated Patients of
Glioblastoma Multiforme.
Neurol
India. 2023 Apr 6;71(Supplement):S183-S188∟.
doi: 10.4103/0028-3886.373625?
PMID: 37026351∟.
Observational study. ˍ
Ronsley R, Triscott J, Stanek J,
Rassekh SR, Lum A, Cheng S, Goddard K, McConnell D, Strahlendorf
C, Singhal A, Finlay JL, Yip S, Dunham C, Hukin J.
Outcomes
of a radiation sparing approach in medulloblastoma by subgroup in
young children: an institutional review.
Childs
Nerv Syst. 2023 Apr 6∟.
doi: 10.1007/s00381-023-05918-z∟.
PMID: 37022464∟.
Observational study. ˍ
Ding Y, Wang Q, Wang F, Wu N, Li J,
He X, Pan H, Wang L.
TTFields
Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case
Report.
Brain
Sci. 2023 Apr 7;13(4):633∟.
doi: 10.3390/brainsci13040633∟.
PMID: 37190598∟.
Case report. ˍ
Prener M, Opheim G, Simonsen HJ,
Engelmann CM, Ziebell M, Carlsen J, Paulson OB.
Delineation
of Grade II and III Gliomas Investigated by 7T MRI: An
Inter-Observer Pilot Study.
Diagnostics
(Basel). 2023 Apr 7;13(8):1365∟.
doi: 10.3390/diagnostics13081365∟.
PMID: 37189466∟.
Interventional study. ˍ
*
Youssef G, Rahman R, Bay C, Wang W,
Lim-Fat MJ, Arnaout O, Bi WL, Cagney DN, Chang YS, Cloughesy TF,
DeSalvo M, Ellingson BM, Flood TF, Gerstner ER, Gonzalez Castro
LN, Guenette JP, Kim AE, Lee EQ, McFaline-Figueroa JR, Potter CA,
Reardon DA, Huang RY, Wen PY.
Evaluation of Standard Response
Assessment in Neuro-Oncology, Modified Response Assessment in
Neuro-Oncology, and Immunotherapy Response
Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent
Glioblastoma.
J
Clin Oncol. 2023 Apr 7:JCO2201579∟.
doi: 10.1200/JCO.22.01579∟.
PMID: 37027809∟.
Observational study˰ ˍ
Cuccarini V, Savoldi F, Mardor Y, Last D, Pellegatta S, Mazzi F,
Bruzzone MG, Anghileri E, Pollo B, Maddaloni L, Russo C, Bocchi E,
Pinzi V, Eoli M, Aquino D.
Response
assessment of GBM during immunotherapy by delayed contrast
treatment response assessment maps.
Front
Neurol. 2024 Apr 8;15:1374737. doi:
10.3389/fneur.2024.1374737. PMID:
38651109. Observational study. ˍ
Msheik A, Fares Y, Hamoud M, Atat
R.
Unraveling
the Complexity of Multicentric Gliomas: Insights Into Chronicity
and Genetic Aberrations.
Cureus.
2023 Apr 8;15(4):e37284∟.
doi: 10.7759/cureus.37284∟.
PMID: 37168179∟.
Case
report. ˍ
Muller Bark J, Karpe AV, Doecke JD,
Leo P, Jeffree RL, Chua B, Day BW, Beale DJ, Punyadeera C.
A
pilot study: Metabolic profiling of plasma and saliva samples from
newly diagnosed glioblastoma patients.
Cancer
Med. 2023 Apr 9∟.
doi: 10.1002/cam4.5857∟.
PMID: 37031458∟.
Interventional study. ˍ
Torres-Espíndola LM, Pérez-De Marcos JC,
Castillejos-López M, Velasco-Hidalgo L, Cárdenas-Cardós
R, De Uña-Flores A, Salinas-Lara C, Caballero-Salazar S,
Fernández-Plata R, Aquíno-Gálvez A.
Factors
Influencing Mortality in Children with Central Nervous System
Tumors: A Cohort Study on Clinical Characteristics and Genetic
Markers.
Genes
(Basel). 2024 Apr 9;15(4):473. doi:
10.3390/genes15040473. PMID:
38674407. Observational study. ˍ
Bartlett S, Nagaraja TN, Griffith
B, Farmer KG, Van Harn M, Haider S, Hunt RJ, Cabral G, Knight RA,
Valadie OG, Brown SL, Ewing JR, Lee IY.
Persistent
Peri-Ablation Blood-Brain Barrier Opening After Laser Interstitial
Thermal Therapy for Brain Tumors.
Cureus.
2023 Apr 10;15(4):e37397∟.
Doi: 10.7759/cureus.37397∟.
PMID: 37182017∟.
Observational
study. ˍ
Halefoglu AM, Camurcuoglu E, Tanik
C, Kizilkaya O, Yilmaz A.
Predictive
role of magnetic resonance imaging in the distinction of
isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus
glioblastomas.
Acta
Radiol. 2023 Apr 10:2841851231165282∟.
doi: 10.1177/02841851231165282∟.
PMID: 37038636∟.
Observational study˰ ˍ
Altieri R, Certo F, Pacella D,
Cammarata G, Garozzo M, Broggi G, Caltabiano R, Magro G, Russo G,
Cosentino S, Ippolito M, Barbagallo G.
Metabolic
delineation of IDH1 wild-type glioblastoma surgical anatomy: how
to plan the tumor extent of resection.
J
Neurooncol. 2023 Apr 11∟.
doi: 10.1007/s11060-023-04305-7∟.
PMID: 37039952∟.
Observational study˰ ˍ
Jarmuzek P, Wawrzyniak-Gramacka E, Morawin B, Tylutka A,
Zembron-Lacny A.
Diagnostic and
Prognostic Value of Circulating DNA Fragments in Glioblastoma
Multiforme Patients.
Int
J Mol Sci. 2024 Apr 11;25(8):4221. doi:
10.3390/ijms25084221. PMID:
38673808. Observational study. ˍ
Liu
V, Wetzel EA, Eldred BSC, Zapanta Rinonos S, Prins TJ, Khanlou N,
Liau LM, Chong R, Nghiemphu PL, Cloughesy TF, Ellingson BM, Lai
A.
A
single-institution retrospective analysis of pathologically
determined malignant transformation in IDH
mutant
glioma patients.
Neurooncol
Adv. 2023 Apr 11;5(1):vdad036∟.
doi: 10.1093/noajnl/vdad036∟.
PMID: 37152809∟.
Observational
study. ˍ
Yuile A, Lee A, Moon EA, Hudson A,
Kastelan M, Miller S, Chan D, Wei J, Back MF, Wheeler HR.
PSMA
Expression Correlates with Improved Overall Survival and VEGF
Expression in Glioblastoma.
Biomedicines.
2023 Apr 11;11(4):1148∟.
doi: 10.3390/biomedicines11041148∟.
PMID: 37189766∟.
Observational study. ˍ
*
She L, Mao X, Su L, Liu
Z.
Prognostic
evaluation of patients with glioblastoma using a new score
prediction model.
Eur
J Surg Oncol. 2023 Apr 12:S0748-7983(23)00438-9∟.
doi: 10.1016/j.ejso.2023.04.001∟.
PMID: 37076410∟.
Observational study˰ ˍ
Syed HR, Kilburn L, Fonseca A,
Nazarian J, Oluigbo C, Myseros JS, Packer RJ, Keating
RF.
First-in-human
sonodynamic therapy with ALA for pediatric diffuse intrinsic
pontine glioma: a phase 1/2 study using low-intensity focused
ultrasound : Technical communication.
J
Neurooncol. 2023 Apr 12∟.
doi: 10.1007/s11060-023-04269-8∟.
PMID: 37046110∟.
Interventional study˰ ˍ
Cohen
A, Noxon V, Dhamane A, Bruette R, Shah S, Hines DM, Alfred T, Luo
X.
Effectiveness
and safety of anticoagulants among venous thromboembolism cancer
patients with and without brain cancer.
Thromb
Res. 2023 Apr 13;226:117-126∟.
doi: 10.1016/j.thromres.2023.04.009∟.
PMID: 37146438∟.
Observational
study. ˍ
Elmuti L, Amundson J, Oberman E,
Kamat A, Sedig L, Lastra RR, Aldape K, Quezado M, Pratt DW, Cimino
PJ, Abdullaev Z, Pytel P, Applebaum MA, Bennett JA.
Diffuse
Pediatric-type High-grade Glioma Arising in an Ovarian Mature
Cystic Teratoma.
Int
J Gynecol Pathol. 2023 Apr 13∟.
doi: 10.1097/PGP.0000000000000954∟.
PMID: 37046379∟.
Case report˰ ˍ
Gregory TA, Mastall M, Lin H, Hess
KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD,
Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS,
Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D,
Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado
M, Majd NK.
Characterization
of recurrence patterns and outcomes of medulloblastoma in adults:
The University of Texas MD Anderson Cancer Center
experience.
Neurooncol
Adv. 2023 Apr 13;5(1):vdad032∟.
doi: 10.1093/noajnl/vdad032∟.
PMID: 37114244∟.
Observational study. ˍ
Hassan U, Amer F, Hussain M,
Mushtaq S, Loya A, Abu Bakar M.
Gemistocytic
Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A
Histopathological and Survival Analysis.
Cureus.
2023 Apr 13;15(4):e37542∟.
doi: 10.7759/cureus.37542∟.
PMID: 37193447∟.
Observational study. ˍ
Wei Y, Li G, Feng J, Wu F, Zhao Z,
Bao Z, Zhang W, Su X, Li J, Qi X, Duan Z, Zhang Y, Vega SF, Jakola
AS, Sun Y, Carén H, Jiang T, Fan X.
Stalled
oligodendrocyte differentiation in IDH-mutant gliomas.
Genome
Med. 2023 Apr 13;15(1):24∟.
doi: 10.1186/s13073-023-01175-6∟.
PMID: 37055795∟.
Laboratory investigation. ˍ
Subbiah V, Kreitman RJ, Wainberg
ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA,
Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P,
Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A,
Passos VQ, Ilankumaran P, Bang YJ.
Dabrafenib
plus trametinib in BRAFV600E-mutated rare cancers: the phase 2
ROAR trial.
Nat
Med. 2023 Apr 14∟.
doi: 10.1038/s41591-023-02321-8∟.
PMID: 37059834∟.
Interventional study. ˍ
*
Kim JE, Park JE, Park SY, Kim YH,
Hong CK, Kim JH, Kim HS.
Defining
subventricular zone involvement to predict the survival of
patients in isocitrate dehydrogenase-wild type glioblastoma:
validation in a prospective registry.
Eur
Radiol. 2023 Apr 15∟.
doi: 10.1007/s00330-023-09625-w∟.
PMID: 37060448∟.
Observational study˰ ˍ
Thivat E, Casile M, Moreau J,
Molnar I, Dufort S, Seddik K, Le Duc G, De Beaumont O, Loeffler M,
Durando X, Biau J.
Phase
I/II study testing the combination of AGuIX nanoparticles with
radiochemotherapy and concomitant temozolomide in patients with
newly diagnosed glioblastoma (NANO-GBM trial protocol).
BMC
Cancer. 2023 Apr 15;23(1):344∟.
doi: 10.1186/s12885-023-10829-y∟.
PMID: 37060055∟.
Interventional study protocol. ˍ